ProMetic joint venture product for blood transfusion gets CE mark

By Lisa Kerner

Charlotte, N.C., Sept. 26 - Pathogen Removal and Diagnostic Technologies, Inc., a joint venture between ProMetic Life Sciences Inc. and the American Red Cross, along with MacoPharma SA, announced that their prion capture filter, P-Capt, received European regulatory approval (CE mark).

Performance studies showed a reduction of infectivity of more than 99.9% in a red blood cell concentrate spiked with a homogenate from a scrapie infected brain, according to a news release.

Pathogen Removal said the product is also being studied by the National Blood Service agencies of the United Kingdom and Ireland.

MacoPharma is a health-care company based in Lille, France. ProMetic is a Montreal-based biopharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.